

ROS Therapeutics welcomes Troels Herlin, Professor, MD, DMSc as a member of its Medical Advisory Board.

March 01, 2021

ROS Therapeutics proudly welcomes Troels Herlin, Professor, MD, DMSc as a member of the company's newly established Medical Advisory Board.

Since Herlin became a specialist in pediatrics in 1988, he has had profound impact on pediatric rheumatology in Denmark and abroad. He established West Denmark - Center for Pediatric Rheumatology at the department of Pediatrics at Aarhus University Hospital in 1991. In 2006, He became clinical professor in pediatric rheumatology at Aarhus University Hospital. He was co-founder of the Danish Pediatric Rheumatology Society, where he was elected chairman from 2006-2012 and 2015-2019. He has been a member of the Rheumatology Research Council of the Danish Rheumatism Association from 1993-2001. Troels has published more than 270 peer-reviewed articles, book chapters and proceedings, predominantly regarding clinical studies in juvenile idiopathic arthritis, arthritis pain and autoinflammation.

"I am so excited that we have succeeded in convincing Troels to advise us. The expertise he has in pediatric medicine, decades long experience in the use of methotrexate to treat juvenile arthritis and other childhood diseases and his internationally recognized network with other Key Opinion Leaders in the field, makes Troels Herlin an outstanding capacity for ROS Therapeutics", says Hanne Damgaard Jensen, CEO.

- "It will be very exciting to contribute to the development of Trexior. I do believe that this product has substantial potential for improving the treatment of juvenile idiopathic arthritis (JIA)", says Troels Herlin.

About Trexior™: Trexior is an innovative proprietary and potentially best-in-class orally delivered methotrexate therapy. Several of the shortcomings of existing methotrexate therapies, whether oral or injections, are sought overcome with Trexior.

About methotrexate: Methotrexate is a cornerstone treatment for JIA, one of the most common childhood diseases, as well as for rheumatoid arthritis (RA), a common autoimmune inflammatory disease of adults. Since the early 90'ies, MTX has had a secure place in the treatment of these diseases and has been shown to have a synergistic relationship with biological therapies.

About ROS Therapeutics: ROS Therapeutics ApS is a development stage pharmaceutical company, committed to optimize the treatment experience with methotrexate and address unmet needs of children with JIA and other autoimmune and chronic inflammatory conditions.

For further information please contact:

Hanne Damgaard Jensen, CEO ROS Therapeutics; hdj@rosterapeutics.com; Tel: +45 4078 6888